Pharmaceutical Contract Research Laboratory
This pharmaceutical Contract Research Organisation (CRO) is located in Canada with a long-standing track-record in delivering GLP bioanalytical, in vitro/in vivo DM/PK and CMC analytical chemistry studies supporting preclinical and clinical Phase I to Phase III development, by a team of very dependable and knowledgeable staff. This CRO is operating with a proven reputation within a large global clientele including biotech and pharmaceutical companies generating steady recurring organic growth year-to-year. Rapid future growth in revenue and strategic value with both preclinical and clinical CRO business is realizable by a strategic buyer.
A strategic preclinical or clinical CRO buyer could benefit from the acquisition of a proven client base, expansion into new areas of pharmaceutical GLP laboratory capabilities, or complement their current operations with an addition of this strategic location in Canada. An optional adjacent rodent DM/PK and xenograft SPF animal facility is also separately or jointly available based on strategic-fit to interested buyers.
This pharmaceutical laboratory CRO is managed by a team of highly experienced and long-term senior staff who will be a part of the transition to strategic new ownership. The current owner is committed to remain in managing the integration to a new ownership for a negotiable period of time to ensure a smooth transition.
Approximately 6,000 sq. ft. of owner occupied GLP bioanalytical and analytical chemistry laboratory space. An adjacent 3,000 sq. ft. rodent animal facility operating with AAALAC and CCAC standards is also available as an optional component in this transaction.
|Net Income $||471,306||236,187||613,047||655,960||721,556|